European Journal of Cancer
Volume 41, Issue 4 , Pages 502-507 , March 2005

Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone – finally an effective chemotherapy

Received 6 December 2004 ,Accepted 7 December 2004.

References 

  1. Greenlee RT, Hill-Harmon B-H, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36
  2. Reese DM, Small EJ. Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin N Am. 1999;26(2):311–321viii. review
  3. Martel CL, Gumerlock PH, Meyers FJ, et al. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 2003;29:171–187
  4. Heidenreich A, Knobloch von R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol. 2000;39:121–130
  5. Yagoda A, Petrylak DP. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098–1109
  6. Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology. 2002;60:94–100
  7. Sternberg CN. What’s new in the treatment of advanced prostate cancer. Eur J Cancer. 2003;39:136–146
  8. Tannock IF, Osoba D, Stockler R, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764
  9. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study. J Clin Oncol. 1999;17:2506–2513
  10. Picus J, Schultz M. Docetaxel (Taxotere) as mono-therapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26:14–18
  11. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol. 1997;79:196–202
  12. Petrylak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958–967
  13. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999;10:33–38
  14. Savarese DM, Halabi S, Hars V, et al. For the Cancer and Leukemia group B. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final Report of CALGB 9780. J Clin Oncol 2001, 19(9), 2509–16
  15. Hudes GR, Manola J, Conroy J, et al. Phase II study of weekly paclitaxel (P) by 1-h infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group (abstract). Proc Am Soc Clin Oncol. 2001;20:175a
  16. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. Phase II evaluations of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002;94:1457–1465
  17. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26:14–18
  18. Beer TM, Pierce WC, Lowe BA, et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273–1279
  19. Tannock IF, Wit de R, Berry WR, et al. For the TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004, 351, 1502–12
  20. Wit de R, Eisenberger MA, Tannock IF, et al. A multicenter phase III comparison of docetaxel+prednisone (P) and mitoxantrone (MTZ)+P in patients with androgen-independent prostate cancer (AIPC): secondary analysis of survival in patient subgroups. The TAX 327 investigators. Presented at ESMO 2004, Vienna, Austria, September 2004. Abstract Book of the 29th ESMO Congress. Ann Oncol 2004, 15(suppl. 3), iii12 [abstr. 44IN]
  21. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med. 2004;351:1513–1520

PII: S0959-8049(04)00994-3

doi: 10.1016/j.ejca.2004.12.007

European Journal of Cancer
Volume 41, Issue 4 , Pages 502-507 , March 2005

Article Tools